1. Home
  2. SMID vs MOLN Comparison

SMID vs MOLN Comparison

Compare SMID & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smith-Midland Corporation

SMID

Smith-Midland Corporation

HOLD

Current Price

$35.11

Market Cap

151.1M

Sector

Industrials

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$4.10

Market Cap

144.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SMID
MOLN
Founded
1960
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Building Materials
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
151.1M
144.0M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
SMID
MOLN
Price
$35.11
$4.10
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$8.38
AVG Volume (30 Days)
6.1K
1.9K
Earning Date
04-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
62.76
N/A
EPS
2.36
N/A
Revenue
$93,446,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$374.07
P/E Ratio
$14.92
N/A
Revenue Growth
19.03
N/A
52 Week Low
$25.60
$3.41
52 Week High
$43.62
$5.36

Technical Indicators

Market Signals
Indicator
SMID
MOLN
Relative Strength Index (RSI) 63.36 43.28
Support Level $35.80 $3.94
Resistance Level $36.89 $4.54
Average True Range (ATR) 1.32 0.06
MACD 0.26 -0.02
Stochastic Oscillator 100.00 0.00

Price Performance

Historical Comparison
SMID
MOLN

About SMID Smith-Midland Corporation

Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

Share on Social Networks: